Astellas Pharma Inc. 4503

This article first appeared on GuruFocus. Astellas Pharma Inc (ALPMF) recently announced a total dividend of $0.25 per share, with the ex-dividend date set for 2026-09-29. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the appointment of Glenn Sblendorio, M.B.A., as Chairman of its Board of Directors. Mr. Sblendorio is a seasoned biotechnology executive and board member with more than three decades of experience leading corporate strategy, finance, business development and capital markets initiatives. Most recently, he was Chief Executive Officer of IVERIC bio, Inc. (acquired by

Astellas Pharma shares have quietly built a strong track record, which raises a simple question for anyone looking at the stock today. Are the current cash flows of Astellas Pharma, and what investors expect them to deliver over time, enough to justify where the share price now sits? Over the past 5 years the stock has returned 54.9%, which puts real weight on whether the current price still lines up with the cash being generated by the business. The company relies heavily on its portfolio...

Astellas Pharma CEO Naoki Okamura and 2375 Waterview Drive (Astellas, Transwestern)Astellas Pharmaceutical is testing the waters of the suburban Chicago office market by putting its office complex in Northbrook up for sale. Japan-based Astellas’s office property spans two buildings at 2375 Waterview Drive and is being billed as a potential sale-leaseback opportunity. The company occupies 84,887 square feet in the south building on the property, according to Crain’s. The total two-building proper

AstellasPharma Inc. (TSE: 4503, President and CEO: NaokiOkamura, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-targeted protein degrader, versus docetaxel in people with KRAS G12D-mutated locally advanced (unresectable) or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after initial platinum-based chemotherapy and checkpoint inhibitor therapy (CPI).1

President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

These deals will require the companies to provide MFN prices to state Medicaid programmes nationally.

Trump expanded his drug pricing deal to 26 pharma firms as UBS says healthcare stocks still have room to climb.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has reached an agreement with the U.S. government that reflects our commitment to patient access, affordability and innovation, while reinforcing Astellas' longstanding commitment to the U.S. healthcare system.

The nine drug companies committed to collectively invest at least $19.6 billion in U.S. manufacturing in the near term.

Astellas Pharma (TSE:4503) has started dosing the first patient in a Phase 3 trial of ASP2138 for CLDN18.2-positive and HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma. The study focuses on a patient group with poor outcomes and limited targeted treatment options. The Phase 3 trial marks an important step in Astellas Pharma's efforts to advance its immuno-oncology pipeline. Investors tracking Astellas Pharma's oncology work may also want to review other cancer...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative.1

ASEKY, ALPMY and ATS have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2026.

COIN, ALPMY and MUX have been added to the Zacks Rank #5 (Strong Sell) List on August 6th, 2026.

Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for […]

Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnin

NEW YORK & TOKYO, July 10, 2026--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant (before and after surgery) treatment for adult patients w